These results are also aligned with current guideline recommendations for SGLT2 inhibitors in patients with T2DM at high cardiovascular risk and are supported by large landmark RCTs such as EMPA-REG OUTCOME [3] and DECLARE-TIMI 58 [5]. Here, SLC5A2 is linked to type 2 diabetes mellitus.